Mayne Pharma faces potential class action over US antitrust case
Class Actions 2020-08-10 3:54 pm By Christine Caulfield | Melbourne
Please login to bookmark Close

ASX-listed generic drug maker Mayne Pharma is facing a possible shareholder class action over disclosures related to US price-fixing allegations against the ASX-listed company.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au